Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome
- Conditions
- Fragile X-Associated Tremor/Ataxia SyndromeFragile X Premutation Carriers
- Interventions
- Drug: Placebo
- Registration Number
- NCT00584948
- Lead Sponsor
- University of California, Davis
- Brief Summary
The purpose of this study is to determine if memantine is effective in treating symptoms of Fragile X-associated Tremor Ataxia Syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 94
- Fragile X premutation carrier (CGG repeat 55-200)with neurological symptoms; Clinical FXTAS Stage 1-5
- Previous reaction to memantine
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Memantine Memantine -
- Primary Outcome Measures
Name Time Method Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II) One Year The BDS-II is a 9-item, 27-point instrument that measures executive function as the capacity for behavioral and attentional self-regulation. Total score is a sum of the 9 items, with a range of 0-27, in which a higher score indicates a better performance.
Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale 1 year The CATSYS is a set of computer assisted diagnostic instruments that can measure intention tremor, postural tremor, postural sway, manual coordination and reaction time. The tremor intensity is defined as the root mean square of accelerations, recorded in the 0.9 Hz to 15.0 Hz band during the test period. Unit is measured in m/s2
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
UC Davis MIND Institute
🇺🇸Sacramento, California, United States
University of Colorado Health Sciences Center
🇺🇸Aurora, Colorado, United States